[1]
|
Li, Q., Cao, M., Lei, L., et al. (2022) Burden of Liver Cancer: From Epidemiology to Prevention. Chinese Journal of Cancer Research, 34, 554-566. https://doi.org/10.21147/j.issn.1000-9604.2022.06.02
|
[2]
|
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版). 肿瘤综合治疗电子杂志, 2022, 8(2): 16-53.
|
[3]
|
Rajesh, S., George, T., Philips, C.A., et al. (2020) Transjugular Intrahepatic Portosystemic Shunt in Cirrhosis: An Exhaustive Critical Update. World Journal of Gastroenterology, 26, 5561-5596. https://doi.org/10.3748/wjg.v26.i37.5561
|
[4]
|
Matsui, O., Kadoya, M., Kameyama, T., et al. (1991) Benign and Malignant Nodules in Cirrhotic Livers: Distinction Based on Blood Supply. Radiology, 178, 493-497. https://doi.org/10.1148/radiology.178.2.1846240
|
[5]
|
Lokken, R.P., Kerlan Jr., R.K., Chung, Y.C., et al. (2021) Hepatic Toxicity after Selective Chemoembolization Is Associated with Decreased Survival among Patients with Hepatocellular Carcinoma. American Journal of Roentgenology, 216, 1283-1290. https://doi.org/10.2214/AJR.20.23478
|
[6]
|
武思彤, 吕天石, 曹守金, 等. TIPS序贯TACE、靶向和/或免疫治疗BCLCD期原发性肝细胞癌伴严重门静脉高压并发症[J]. 中国介入影像与治疗学, 2023, 20(1): 12-16.
|
[7]
|
Ruohoniemi, D.M., Taslakian, B., Aaltonen, E.A., et al. (2020) Comparative Analysis of Safety and Effi-cacy of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma in Patients with and without Pre-Existing Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology, 31, 409-415.
https://doi.org/10.1016/j.jvir.2019.11.020
|
[8]
|
Chen, X., Qiu, Z.K., Wang, G.B., et al. (2021) Effect of Transjugular Intrahepatic Portosystemic Shunt on Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Diagnostic and Interventional Radiology, 27, 671-676. https://doi.org/10.5152/dir.2021.20358
|
[9]
|
Moher, D., Liberati, A., Tetzlaff, J., et al. (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine, 6, e1000097. https://doi.org/10.1371/journal.pmed.1000097
|
[10]
|
肖晋昌. TIPS联合TACE治疗肝癌伴门静脉高压食管胃静脉曲张出血的临床疗效[J]. 临床放射学杂志, 2022, 41(6): 1138-1142.
|
[11]
|
Lu, H.L., Xuan, F.F., Luo, Y.C., et al. (2021) Efficacy and Safety of Transjugular Intrahepatic Portosystemic Shunt Combined with Transcatheter Emboliza-tion/Chemoembolization in Hepatocellular Carcinoma with Portal Hypertension and Arterioportal Shunt. Abdominal Radiology, 46, 5417-5427. https://doi.org/10.1007/s00261-021-03214-5
|
[12]
|
徐文海. 经导管动脉化疗栓塞治疗经颈静脉肝内门体分流术后肝细胞癌临床应用评价[J]. 入放射学杂志, 2021, 30(10): 1052-1056.
|
[13]
|
Luo, S.H., Chu, J.G., Huang, H., et al. (2019) Safety and Efficacy of Transjugular Intrahepatic Portosystemic Shunt Combined with Palliative Treatment in Patients with Hepatocellular Carcinoma. World Journal of Clinical Cases, 7, 1599-1610. https://doi.org/10.12998/wjcc.v7.i13.1599
|
[14]
|
Miura, J.T., Rilling, W.S., White, S.B., et al. (2015) Safety and Efficacy of Transarterial Chemoembolization in Patients with Transjugular Intrahepatic Portosystemic Shunts. HPB, 17, 707-712. https://doi.org/10.1111/hpb.12433
|
[15]
|
Wang, Z., Zhang, H., Zhao, H., et al. (2014) Repeated Transcatheter Arterial Chemoembolization Is Safe for Hepatocellular Carcinoma in Cirrhotic Patients with Transjugular Intrahepatic Portosystemic Shunt. Diagnostic and Interventional Radiology, 20, 487-491. https://doi.org/10.5152/dir.2014.13493
|
[16]
|
Kuo, Y.C., Kohi, M.P., Naeger, D.M., et al. (2013) Efficacy of TACE in TIPS Patients: Comparison of Treatment Response to Chemoembolization for Hepatocellular Carcinoma in Patients with and without a Transjugular Intrahepatic Portosystemic Shunt. CardioVascular and Interventional Radiology, 36, 1336-1343.
https://doi.org/10.1007/s00270-013-0698-8
|
[17]
|
Kang, J.W., Kim, J.H., Ko, G.Y., et al. (2012) Transarterial Chemoembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt. Acta Radiologica, 53, 545-550. https://doi.org/10.1258/ar.2012.110476
|
[18]
|
Hung, M.L. and Lee, E.W. (2019) Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension: Review and Update of the Literature. Clinics in Liver Disease, 23, 737-754.
https://doi.org/10.1016/j.cld.2019.07.004
|
[19]
|
Dong, H., Zhang, C., Li, Z., et al. (2021) Trans-Jugular Intrahepatic Portosystemic Shunt in Patients with Hepatic Cellular Carcinoma: A Preliminary Study. Journal of Cancer Research and Therapeutics, 17, 784-789.
https://doi.org/10.4103/jcrt.jcrt_467_21
|
[20]
|
Kohi, M.P., Fidelman, N., Naeger, D.M., et al. (2013) Hepatotoxicity after Transarterial Chemoembolization and Transjugular Intrahepatic Portosystemic Shunt: Do Two Rights Make a Wrong? Journal of Vascular and Interventional Radiology, 24, 68-73. https://doi.org/10.1016/j.jvir.2012.08.032
|
[21]
|
Han, T., Yang, X., Zhang, Y., et al. (2019) The Clinical Safety and Efficacy of Conventional Transcatheter Arterial Chemoembolization and Drug-Eluting Beads-Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Meta-Analysis. BioScience Trends, 13, 374-381. https://doi.org/10.5582/bst.2019.01153
|
[22]
|
Fan, W., Guo, J., Zhu, B., et al. (2021) Drug-Eluting Beads TACE Is Safe and Non-Inferior to Conventional TACE in HCC Patients with TIPS. European Radiology, 31, 8291-8301. https://doi.org/10.1007/s00330-021-07834-9
|
[23]
|
Miyayama, S. (2019) Ultraselective Conventional Transarterial Chemoembolization: When and How? Clinical and Molecular Hepatology, 25, 344-353. https://doi.org/10.3350/cmh.2019.0016
|
[24]
|
Wang, Z.M. and Wu, Z.Q. (1998) The Chinical Significance of DSA of Celiac Artery in Primary Hepatoma Interventional Radiology Department, Tang Du Hospital the Forth Military Medical University (Xian 710038). Chinese Journal of Medical Imaging Technology, 14, 117-118.
|
[25]
|
Shao, Z., Liu, X., Peng, C., et al. (2021) Combination of Transcatheter Arterial Chemoembolization and Portal Vein Embolization for Patients with Hepatocellular Carcinoma: A Review. World Journal of Surgical Oncology, 19, Article No. 293. https://doi.org/10.1186/s12957-021-02401-4
|
[26]
|
Okuda, K., Musha, H., Yamasaki, T., et al. (1977) Angiographic Demonstration of Intrahepatic Arterio-Portal Anastomoses in Hepatocellular Carcinoma. Radiology, 122, 53-58. https://doi.org/10.1148/122.1.53
|
[27]
|
Huang, M.S., Lin, Q., Jiang, Z.B., et al. (2004) Comparison of Long-Term Effects between Intra-Arterially Delivered Ethanol and Gelfoam for the Treatment of Severe Arterioportal Shunt in Patients with Hepatocellular Carcinoma. World Journal of Gastroenterology, 10, 825-829. https://doi.org/10.3748/wjg.v10.i6.825
|
[28]
|
Wu, H., Zhao, W., Zhang, J., et al. (2018) Clinical Characteristics of Hepatic Arterioportal Shunts Associated with Hepatocellular Carcinoma. BMC Gastroenterology, 18, Article No. 174. https://doi.org/10.1186/s12876-018-0899-3
|
[29]
|
Hao, M.Z., Lin, H.L., Chen, Q.Z., et al. (2017) Safety and Effi-cacy of Transcatheter Arterial Chemoembolization with Embospheres in Treatment of Hepatocellular Carcinoma. Journal of Digestive Diseases, 18, 31-39.
https://doi.org/10.1111/1751-2980.12435
|
[30]
|
Yao, J., Zuo, L., An, G., et al. (2015) Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension. Journal of Gastrointestinal and Liver Diseases, 24, 301-307. https://doi.org/10.15403/jgld.2014.1121.243.yao
|
[31]
|
赵孟菲, 刘福全, 岳振东, 等. 原发性肝癌伴门静脉高压症TIPSS术后肝衰竭高危因素分析[J]. 中国临床医学影像杂志, 2013, 24(5): 328-333.
|
[32]
|
Zou, X., Xue, M. and Li, J. (2021) Combined Use of Transjugular Intrahepatic Portosystemic Shunt and Transarterial Chemoembolization in the Treatment of Esophageal and Gastric Variceal Bleeding: A Retrospective Study of 80 Patients with Hepatocellular Carcinoma and Portal Hypertension. Medical Science Monitor, 27, e934436.
https://doi.org/10.12659/MSM.934436
|